Bristol-Myers Squibb to Acquire Celgene

On Jan. 22, 2018, Celgene announced they had acquired Juno Therapeutics. Juno’s CAR-T, JCAR017, looks very promising in CLL and is very similar to the CAR-T that I took in my successful clinical trial. One year later, on Jan. 3, 2019, Bristol-Myers Squibb announced plans to acquire Celgene. Here is a link to press coverage: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-acquire-celgene-create-premier-innovative

AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)
May 29, 2019

May 15, 2019: FDA approved venetoclax in combination with obinutuzumab for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
May 20, 2019

FDA places a partial hold on all venetoclax clinical trials for multiple myeloma (MM) patients
March 20, 2019

Venetoclax Will be Paid for in Australia
February 26, 2019

CMS approves CAR-T therapy payment, but with significant strings attached
February 20, 2019

The FDA’s 10th approval of ibrutinib, this time in combination with obinutuzumab for frontline therapy for CLL
January 29, 2019